OTCMKTS:XSNX NovAccess Global (XSNX) Stock Price, News & Analysis → Urgent dollar warning (From Stansberry Research) (Ad) Free XSNX Stock Alerts $0.0070 0.00 (0.00%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.0060▼$0.007050-Day Range$0.01▼$0.0352-Week Range$0.01▼$0.22Volume109,135 shsAverage Volume979,712 shsMarket Capitalization$269,045.10P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get NovAccess Global alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About NovAccess Global Stock (OTCMKTS:XSNX)NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.Read More XSNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XSNX Stock News HeadlinesApril 30, 2024 | finance.yahoo.comNovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 26, 2024 | americanbankingnews.comNovAccess Global Inc. (OTCMKTS:XSNX) Sees Large Decline in Short InterestMay 2, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.April 23, 2024 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) and NovAccess Global (OTCMKTS:XSNX) Financial SurveyFebruary 7, 2024 | msn.comNovAccess Global Faces Default and Uncertain Rescue DealJanuary 2, 2024 | msn.comNovAccess Global jumps on announcing $10.7 million financingJanuary 2, 2024 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finance.yahoo.comNovAccess Global Announces $10.7 Million FinancingMay 2, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.December 1, 2023 | finance.yahoo.comNovAccess Global Inc. to Present at the December 7th Virtual Investor SummitNovember 10, 2023 | finance.yahoo.comNovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory BoardNovember 2, 2023 | morningstar.comNovaccess Global Inc XSNXJuly 29, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 27, 2023 | finance.yahoo.comNovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 13, 2023 | finance.yahoo.comNovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness DayJuly 6, 2023 | finance.yahoo.comXSNX - NovAccess Global Inc.June 16, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine DivisionJune 16, 2023 | finance.yahoo.comNovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine DivisionJune 1, 2023 | finance.yahoo.comNovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare TherapiesMay 11, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine AdvancementsMay 11, 2023 | finance.yahoo.comNovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine AdvancementsMarch 15, 2023 | finanznachrichten.deNovAccess Global Inc.: Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon AwardMarch 15, 2023 | finance.yahoo.comDr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon AwardFebruary 16, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global to Present at World Orphan Drug CongressFebruary 16, 2023 | finance.yahoo.comNovAccess Global to Present at World Orphan Drug CongressFebruary 3, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual CongressFebruary 3, 2023 | finance.yahoo.comNovAccess Global Leadership to Present at World Brain Mapping Foundation Annual CongressSee More Headlines Receive XSNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovAccess Global and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/02/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:XSNX CUSIPN/A CIK1039466 Webwww.xsunx.com Phone(213) 642-9268Fax949-266-5823Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,720,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-877.60% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-0.01Miscellaneous Outstanding Shares38,490,000Free Float34,493,000Market Cap$269,430.00 OptionableNot Optionable Beta1.51 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Dwain K. Morris-Irvin M.P.H. (Age 56)MPH, Ph.D., CEO & Director Comp: $155.43kMr. Neil J. Laird (Age 71)Chief Financial Officer Dr. Christopher Wheeler Ph.D.President of Stemvax TherapeuticsKey CompetitorsGelStatOTCMKTS:GSACPredictive Technology GroupOTCMKTS:PREDSkinvisibleOTCMKTS:SKVIAmpio PharmaceuticalsNYSE:AMPETherapix BiosciencesOTCMKTS:TRPXDView All Competitors XSNX Stock Analysis - Frequently Asked Questions How have XSNX shares performed in 2024? NovAccess Global's stock was trading at $0.0201 on January 1st, 2024. Since then, XSNX stock has decreased by 65.2% and is now trading at $0.0070. View the best growth stocks for 2024 here. Are investors shorting NovAccess Global? NovAccess Global saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 400 shares, a drop of 99.4% from the March 31st total of 65,900 shares. Based on an average daily volume of 1,568,900 shares, the days-to-cover ratio is presently 0.0 days. View NovAccess Global's Short Interest. How were NovAccess Global's earnings last quarter? NovAccess Global Inc. (OTCMKTS:XSNX) issued its earnings results on Tuesday, February, 27th. The company reported $0.01 EPS for the quarter. What other stocks do shareholders of NovAccess Global own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovAccess Global investors own include Co-Diagnostics (CODX), iBio (IBIO), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Kopin (KOPN), Ascent Solar Technologies (ASTI) and BioRestorative Therapies (BRTX). How do I buy shares of NovAccess Global? Shares of XSNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:XSNX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovAccess Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
